West Pharm Svcs Stock Price, News & Analysis

West Pharmaceutical Services, traded under the ticker WST, will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 24, 2021, at 10:00 AM ET. The presentation will be accessible via a live audio webcast on their website. West is known for providing high-quality injectable solutions and services, boasting nearly 10,000 employees and generating over $2.15 billion in sales in 2020. The company is headquartered in Exton, Pennsylvania, and is included in the Standard & Poor's 500 index.

West Pharmaceutical Services, Inc. (NYSE: WST) has announced a second-quarter 2021 dividend of $0.17 per share. This dividend will be paid on May 5, 2021, to shareholders recorded as of April 21, 2021. The company, which generated over $2.15 billion in sales in fiscal year 2020, is recognized as a leading provider of injectable solutions and services. With nearly 10,000 employees globally, West plays a crucial role in ensuring the safe delivery of vital medicines.

West Pharmaceutical Services reported strong Q4 and full-year 2020 results, with Q4 net sales of $580.2 million, a 23.3% increase, and full-year net sales of $2.147 billion, up 16.7%. Q4 diluted EPS rose 53.6% to $1.29, while full-year EPS jumped 42.4% to $4.57. The company forecasts 2021 net sales between $2.500 billion and $2.525 billion and EPS of $6.00 to $6.15. Strong sales growth was driven by the Biologics and Generics segments, particularly high-value product components for COVID-19.

West Pharmaceutical Services (NYSE: WST) has announced its plan to release fourth-quarter and full-year 2020 financial results on February 18, 2021, before the market opens. A conference call will follow at 9:00 a.m. ET to discuss the results and future business expectations. Participants can join by dialing 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 4095168. A live broadcast and an online archive of the call will be available on the company's website.

West Pharmaceutical Services has declared a $0.17 dividend per share for Q1 2021, payable on February 3, 2021. Shareholders of record by January 20, 2021 will receive the dividend. Additionally, the Board has authorized a share repurchase program for up to 631,000 shares in 2021, aimed at enhancing shareholder value. The program will be completed by December 31, 2021. West will also present at the J.P. Morgan Healthcare Conference on January 13, 2021, offering insights into its business.

West Pharmaceutical Services, Inc. (NYSE: WST) has appointed Kimberly Banks MacKay as Senior Vice President General Counsel and Corporate Secretary, effective December 8, 2020. She succeeds George L. Miller, who will retire in February 2021. Ms. MacKay joins from The Segal Group, bringing extensive legal experience and knowledge of the regulated pharmaceutical environment, having previously held significant roles at Novartis. The leadership change aims to support West's mission in the injectable drug market, enhancing innovation and compliance.

West Pharmaceutical Services announced a 4Q 2020 dividend increase to $0.17 per share, up from $0.16, marking a 6.25% rise. This dividend is part of the company's commitment to shareholders, representing the 28th consecutive annual increase. The payment will occur on November 18, 2020, for shareholders recorded by November 11, 2020. West's 2019 sales reached $1.84 billion, reflecting ongoing demand for its products in the healthcare sector.

West Pharmaceutical Services, Inc. (NYSE: WST) announced FDA 510(k) clearance and the launch of its Vial2Bag Advanced™ 20mm Admixture Device on Oct. 22, 2020. This innovative, needle-free device facilitates the reconstitution and transfer of medication from vials to IV bags, optimizing pharmacy clean room time and enhancing point-of-care nursing efficiency. Key features include a dual channel design, compatibility with all manufacturers' IV bags, and reduced waste for liquid and powder medications. This advancement supports adherence to USP <797> compounding requirements and aims to improve patient care.

West Pharmaceutical Services (WST) reported a robust third-quarter 2020, achieving net sales of $548.0 million, a 20.1% increase year-over-year. Organic sales grew by 18.2%. The reported diluted EPS rose by 45% to $1.09, with adjusted diluted EPS increasing 46% to $1.15. Full-year sales guidance was raised to between $2.10 billion and $2.11 billion. The company highlighted significant contributions from High-Value Products and Biologics, supported by demand related to COVID-19 treatments and vaccines.